AKT1 Mutation Analysis
To detect and type mutations in nucleotide base positions 49 (codon 17), 517 (codon 173), and 536 (codon 179) of the AKT1 oncogene in a wide range of human malignancies, including colorectal, ovarian, uterine and breast cancers, for prognostic and therapeutic applications.
Performed by Next Gen Sequencing on the 46 gene panel for codons 17 and 49 and Exon 3 codons 17 and 49 on the 53 gene panel. The test is also available by Sanger sequencing.
This assay will detect mutations in nucleotide base positions G49 (1st nucleotide of codon 17), G517 (1st nucleotide of codon 173), and A536 (2nd nucleotide of codon 179). The sensitivity of the Primer extension assay is 5-10% of variant sequence in the background of wild type sequence, whereas, the sensitivity of Sanger sequencing is approximately 20%.
10 mL peripheral blood, 2-5mL bone marrow aspirate, 5mg purified DNA, or 4-10 unstained tissue sections on glass slides along with 1 H&E-stained section.
Please provide a copy of the corresponding pathology report.
Additional charges may apply for tissue extraction.
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.